What Hyloris does
Hyloris Pharmaceuticals adds value to healthcare systems by enhancing the potential of well-known pharmaceuticals. We create new formulas, new dosages and new methods of administration that add value to established products. We expertly investigate and develop products to bring clear benefits to both patients and healthcare professionals.
| 04.08.21 | Hyloris Reports 2021 Half-Year Results: Multiple Potential Value Inflection Points Ahead | ||
| 27.07.21 | Hyloris to Report 2021 Half-Year Results on 4 August 2021 | ||
| 08.07.21 | Hyloris Announces Launch of Maxigesic®IV, a Novel Non-Opioid Pain Treatment, in Key European Markets | ||
| 24.06.21 | Hyloris Successfully Renegotiates License Agreements for Lead Products with the Alter Pharma Group | ||
| 08.06.21 | Hyloris Shareholders Unanimously Approve all Resolutions at 2021 Annual General Meeting | ||
| 07.05.21 | Hyloris Announces Annual General Meeting of Shareholders on 8 June 2021 | ||
| 06.05.21 | Hyloris Announces Extension of Footprint of Maxigesic® IV into South America | ||
| 28.04.21 | Hyloris Announces Major Commercial Partnership in the U.S. for Maxigesic® IV | ||
| 08.04.21 | Hyloris Announces Further Extension of European Footprint of Maxigesic®IV | ||
| 09.03.21 | Hyloris Reports Full Year 2020 Financial Results | ||
| 05.03.21 | Hyloris’ Partner AFT Pharmaceuticals Signs Licensing Agreement with Aguettant for Maxigesic® IV in Eight European Markets | ||
| 03.03.21 | Hyloris to Report its Full Year 2020 Results on 9 March 2021 |
